



prosigna™

Breast Cancer Recurrence
Risk

SYNLAB 
SOLUTIONS IN DIAGNOSTICS

www.synlab-sd.com



Why undergoing this examination?

In recent years, the understanding of breast cancer has evolved significantly, now considered a complex and heterogeneous pathology. Therefore, distinct factors must be considered to determine the patient's prognosis. Women with early-stage breast cancer expressing estrogen receptors usually have a good prognosis. However, in this population, about 50% of recurrences occur after five years of diagnosis. An imminent need in the management of estrogen receptor-positive breast cancer is to identify women at increased risk for late recurrence.

- Approved by the regulatory agencies of the United States (FDA) and Europe (EMA) as a prognostic tool in early breast cancer;
- Provides the assessment of recurrence risk over up to 10 years and the intrinsic subtype.

What is the exam?

Prosigna (PAM50) was developed based on a PAM50 genetic signature that provides the patient's risk of recurrence information (ROR - Risk Of Recurrence) based on three factors: tumor size, intrinsic molecular subtype, and tumor proliferation status.

Extra Information

DOCUMENTATION – Available on the SYNLAB Direct for clients

- Informed Consent;
- Clinical Questionnaire;
- Medical Request.

PREPARATION

- Fasting is not necessary for the exam.



Delivery Time

9 business days



Sample Type

Fragment of tumor tissue in a paraffin block (consult material preparation instructions).

For whom is it indicated?

Postmenopausal women who have undergone mastectomy due to breast cancer and have the following characteristics:

- Hormone receptor-positive, node-negative, stage I and II breast cancer;
- Hormone receptor-positive, node-positive (1-3, 4 or more positive nodes), stage II or IIIA breast cancer.

Technology

nCounter Dx Analysis System.

Additional Information

O laudo contempla distintos parâmetros:

- **Lymph node involvement and Intrinsic subtype** - risk classification and information for therapeutic guidelines.
- **ROR** – numerical value from 0 to 100 related to the 10-year recurrence risk;
- **Risk classification** – Establishes the risk of recurrence in 10 years, classifying into three possible groups: Low risk, intermediate risk, and high risk.

Advantages

SYNLAB GROUP

Guaranteed by the experience of the absolute European leader in laboratory diagnostics.

COMPLETE

- Validated in two clinical studies that evaluated more than 2,400 postmenopausal women with early-stage breast cancer.

Node status	ROR	RISK
Nodes	0-40	Low
	41-60	Intermediate
	61-100	High
Nodes + (1-3)	0-15	Low
	16-40	Intermediate
	41-100	High
Nodes + (≥4)	0-100	High